<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02456571</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00063296</org_study_id>
    <nct_id>NCT02456571</nct_id>
  </id_info>
  <brief_title>CTC Immune Checkpoint</brief_title>
  <official_title>Defining the Relevant Immune Checkpoints Expressed on Metastatic Prostate Cancer Circulating Tumor Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study will explore the prevalence of expression of four immune checkpoint&#xD;
      biomarkers on circulating tumor cells (CTCs) from men with metastatic prostate cancer that&#xD;
      are captured by EpCAM via the CellSearch method, and specifically defined as co expressing&#xD;
      DAPI and cytokeratin, and lacking CD45 expression.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2016</start_date>
  <completion_date type="Actual">June 13, 2019</completion_date>
  <primary_completion_date type="Actual">June 13, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in expression of four immune checkpoint biomarkers (PD-L1, PD-L2, B7-H3, and CTLA-4) on circulating tumor cells (CTCs).</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in expression of four immune checkpoint biomarkers (PD-L1, PD-L2, B7-H3, and CTLA-4) on circulating tumor cells (CTCs).</measure>
    <time_frame>Baseline to 14 months (expected time of progression)</time_frame>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">38</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <description>men with mCRPC starting sipuleucel-T (Provenge) with or without abiraterone acetate or enzalutamide will have CTC enumeration and immune checkpoint characterization at baseline, 3 months, 4-12 weeks after completion of sipuleucel-T, and at progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <description>men with mCRPC with visceral or high risk disease pre-abiraterone/enzalutamide will have CTC enumeration and immune checkpoint characterization at baseline, 3 months, and progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <description>men with high volume metastatic castration sensitive prostate cancer (mCSPC) starting hormonal therapy and docetaxel chemotherapy or who decline docetaxel chemotherapy will have CTC enumeration and immune checkpoint characterization at baseline, 3 months, and progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <description>men with enzalutamide or abiraterone acetate resistant mCRPC will have CTC enumeration and immune checkpoint characterization at baseline (i.e. progression on enzalutamide or abiraterone acetate) and 4-12 weeks after completion of next therapy (ex. radium-223 or chemotherapy)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CTC biomarker expression prevalence</intervention_name>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Duke Cancer Institute Patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Patients will be eligible for inclusion in this study only if all of the following criteria&#xD;
        apply:&#xD;
&#xD;
          1. Histologically confirmed diagnosis of adenocarcinoma of the prostate. Small cell or&#xD;
             neuroendocrine tumors of the prostate are also permitted.&#xD;
&#xD;
          2. Clinical or radiographic evidence of progressive metastatic disease, with progression&#xD;
             defined as a rising PSA, new metastatic lesions (bone or soft tissue), or radiographic&#xD;
             evidence of tumor growth on CT or MRI.&#xD;
&#xD;
          3. Age ≥ 18 years.&#xD;
&#xD;
          4. Ability to understand and the willingness to sign a written informed consent document.&#xD;
&#xD;
        In addition to meeting all of the above criteria, patients must meet all of the criteria&#xD;
        for one of the following groups:&#xD;
&#xD;
        A) mCRPC starting sipuleucel-T (Provenge) with or without abiraterone acetate or&#xD;
        enzalutamide&#xD;
&#xD;
          1. For patients with adenocarcinoma of the prostate (not applicable for patients with&#xD;
             small cell or neuroendocrine tumors of the prostate, or those receiving ADT therapy):&#xD;
             Castrate levels of testosterone (≤ 50 ng/dl)&#xD;
&#xD;
          2. Patient planning to start sipuleucel-T.&#xD;
&#xD;
          3. Enrollment prior to the initiation of sipuleucel-T.&#xD;
&#xD;
        B) mCRPC with visceral or high risk disease pre-abiraterone/enzalutamide&#xD;
&#xD;
          1. For patients with adenocarcinoma of the prostate (not applicable for patients with&#xD;
             small cell or neuroendocrine tumors of the prostate, or those receiving ADT therapy):&#xD;
             Castrate levels of testosterone (≤ 50 ng/dl)&#xD;
&#xD;
          2. Visceral OR high risk disease - must meet one of the following categories:&#xD;
&#xD;
               -  Visceral disease: Radiographic evidence of liver, adrenal, pulmonary, or brain&#xD;
                  metastases&#xD;
&#xD;
               -  High risk disease: Presence of at least 2 of the following factors:&#xD;
&#xD;
                    -  Bone pain requiring opioids&#xD;
&#xD;
                    -  Anemia (Hgb &lt;13 g/dL)&#xD;
&#xD;
                    -  Bone scan progression at baseline&#xD;
&#xD;
                    -  &gt;2 sites of metastatic disease&#xD;
&#xD;
                    -  Karnofsky Performance Status (KPS) ≤ 70&#xD;
&#xD;
                    -  PSA doubling time &lt;3 months&#xD;
&#xD;
          3. Patient planning to start abiraterone acetate or enzalutamide.&#xD;
&#xD;
          4. Enrollment prior to the initiation of abiraterone acetate or enzalutamide.&#xD;
&#xD;
        C) Newly diagnosed metastatic castration sensitive prostate cancer (mCSPC) starting&#xD;
        androgen deprivation therapy&#xD;
&#xD;
          1. Evidence of metastatic disease on radiographic imaging&#xD;
&#xD;
          2. Enrollment within 2 weeks of initiation of androgen deprivation therapy (ADT).&#xD;
&#xD;
          3. Lack of history of hypogonadism&#xD;
&#xD;
        D) Enzalutamide or abiraterone acetate resistant mCRPC&#xD;
&#xD;
          1. For patients with adenocarcinoma of the prostate (not applicable for patients with&#xD;
             small cell or neuroendocrine tumors of the prostate, or those receiving ADT therapy):&#xD;
             Castrate levels of testosterone (≤ 50 ng/dl)&#xD;
&#xD;
          2. Evidence of disease progression on or following enzalutamide or abiraterone acetate,&#xD;
             as defined by one of the following:&#xD;
&#xD;
               -  Radiographic evidence of disease progression as defined by new bone scan lesions&#xD;
                  or growth of existing soft tissue/visceral/lymph node/bone metastases as&#xD;
                  determined by the investigator&#xD;
&#xD;
               -  Clinical progression of disease with cutaneous lesions or palpable lesions in&#xD;
                  absence of radiographic progression&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of intercurrent or past medical or psychiatric illness that would make&#xD;
             participation in a blood drawing protocol difficult or not feasible at the discretion&#xD;
             of the principal investigator or co-investigator(s).&#xD;
&#xD;
          2. Treatment with an anthracycline (including mitoxantrone) within 1 week of CTC&#xD;
             collection, as anthracyclines cause auto-fluorescence of cells.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew J Armstrong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>May 20, 2015</study_first_submitted>
  <study_first_submitted_qc>May 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2015</study_first_posted>
  <last_update_submitted>July 8, 2019</last_update_submitted>
  <last_update_submitted_qc>July 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

